Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01438-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Chenyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center of Kidney Diseases, Jinling Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jia…. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Continuous Renal Replacement Therapy, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ceftazidime-avibactam (CAZ-AVI), a novel antibiotic, is effective in treating infections caused by carbapenem-resistant Gram-negative bacteria. However, in patients receiving continuous renal replacement therapy (CRRT), both the pharmacokinetics (PK) and pharmacodynamics (PD) of the drugs can be significantly altered. Currently, there remains a lack of clear guidelines regarding optimal dosing regimens for CAZ-AVI during CRRT. Prospectively, this study evaluated the PK/PD of CAZ-AVI in 21 critically ill patients receiving CRRT. We collected blood samples at 5–7 sampling points within one administration cycle and then determined the total plasma drug concentrations. Phoenix was used to calculate the PK parameters. The clearance at steady state (CL SS ) of patients receiving CRRT was significantly reduced, and drug exposure was also significantly increased compared to healthy subjects. Notably, four patients demonstrated the free minimum plasma concentrations (fC min ) of CAZ exceeding eight times the MIC, and 90.48% (19 cases) of the patients exhibited CAZ plasma concentrations exceeding the neurotoxicity threshold of 104 mg/L. PK/PD analysis indicated that the standard dosing regimen of 2.5 g every 8 hours of CAZ-AVI may pose a risk of excessive drug exposure. In addition, CRRT was the primary elimination pathway for CAZ-AVI in critically ill patients with acute kidney injury receiving CRRT. Significant differences in extracorporeal clearance were observed between continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemofiltration (CVVH) for both CAZ and AVI; CVVH demonstrated higher clearance for CAZ and AVI compared to CVVHD. To prevent potential toxic reactions, it is urgent to establish a safer and more rational dosing regimen for patients receiving CRRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center of Kidney Diseases, Jinling Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China.
- Jinling Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.
- National Clinical Research Center of Kidney Diseases, Jinling Hospital Affiliated Hospital of Medical school, Nanjing University, Nanjing, Jiangsu, China.
- Department of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical school, Nanjing University, Nanjing, Jiangsu, China.
ORCID-Profile: Huijie Yue, Yongchun Ge
Zitieren
APA
Li, C., Wang, Y., Chen, F., Huang, L., Dong, J., Fan, W., Yue, H., & Ge, Y. (2026). Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01438-25
Vancouver
Li C, Wang Y, Chen F, Huang L, Dong J, Fan W, et al. Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01438-25
BibTeX
@article{Li2026,
author = {Li, Chenyang and Wang, Yi and Chen, Feng and Huang, Lixuan and Dong, Jianhua and Fan, Wenjing and Yue, Huijie and Ge, Yongchun},
title = {Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01438-25}
}
EUVIMED